<< Local parents and pre-school children join Tom Cochrane to launch World Vision's Five for 5 campaign | Summary of third-quarter financial results released by BioSyent >>
Read in | English | 한국어

Comparative analysis of Central and Eastern European policies towards generic and innovative drug applications

Published on November 26, 2009 at 7:06 AM · No Comments

Research and Markets (http://www.researchandmarkets.com/research/db5333/generic_and_innova) has announced the addition of the "Generic and Innovative Drugs Markets in Central and Eastern Europe 2009" report to their offering.

Generic and innovative drugs markets in Central and Eastern Europe 2009 - Comparative analysis, reimbursement policies and development forecasts 2009-2011

The report focuses on a comparative analysis of Central and Eastern European policies towards the use of generic and innovative drug applications and covers such important areas like the legal framework, counterfeit products and reimbursement and pricing policies. The report delivers key data on the total size of the CEE generic and innovative drugs market, the market share for each country in the region and development forecasts up to 2011.

In addition, Generic and innovative drugs markets in Central and Eastern Europe 2009 Comparative analysis, reimbursement policies and development forecasts 2009-2011 provides details on patent and data exclusivity protection trends and facts in the countries analysed as well as scale of counterfeiting in each of the countries.

This report provides a study analysis of the eight generic and innovative drugs markets in the CEE:

  • Bulgaria,
  • Czech Republic,
  • Hungary,
  • Poland,
  • Romania,
  • Russia,
  • Slovakia,
  • Ukraine.

http://www.researchandmarkets.com/research/db5333/generic_and_innova

Posted in: Pharmaceutical News

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading